The last quarter has been an eventful one for UCB, with several positive triggers (following the phase III failure of its Lupus drug, Epratuzumab) – both on the operating as well as the pipeline front – driving the improved momentum and outlook for the company. From the encouraging read-out from its osteoporosis drug Romosozumab to the positive CHMP recommendation for its pipeline epilepsy drug, Brivaracetam, and the successful divestiture of Kremers Urban to US-based Lannett Inc.
18 Dec 2015
UCB fuelled by CVN success and pipeline promise
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
UCB fuelled by CVN success and pipeline promise
UCB S.A. (UCB:WBO) | 0 0 1.1% | Mkt Cap: 13,141m
- Published:
18 Dec 2015 -
Author:
Jyoti Prakash - Pages:
The last quarter has been an eventful one for UCB, with several positive triggers (following the phase III failure of its Lupus drug, Epratuzumab) – both on the operating as well as the pipeline front – driving the improved momentum and outlook for the company. From the encouraging read-out from its osteoporosis drug Romosozumab to the positive CHMP recommendation for its pipeline epilepsy drug, Brivaracetam, and the successful divestiture of Kremers Urban to US-based Lannett Inc.